Advanced Microbubbles Inc

Advanced Microbubbles Inc develops innovative microbubble technologies for medical and industrial applications, enhancing drug delivery systems and imaging clarity. Their focus lies in precision medicine and diagnostics, catering to healthcare markets across North America and Europe. Advanced Microbubbles Inc, founded in 2014 in Newark, US, focuses on the development of advanced microbubble technologies. The company was established by Jameel Feshitan and Shashank Sirsi, with Jameel Feshitan currently serving as CEO.

The company has completed a total of 2 deals, with their most recent financing event occurring on May 14, 2020, where they raised seed funding from SOSV and IndieBio. Advanced Microbubbles Inc. specializes in the development and production of innovative microbubble technologies designed to enhance various applications in the medical and industrial sectors. Their core offerings include advanced microbubble agents that facilitate improved drug delivery systems, particularly in ultrasound therapies.

These microbubbles serve as contrast agents, enhancing imaging clarity while also enabling targeted therapeutic delivery to specific tissues, addressing challenges in precision medicine and diagnostics. The company's products are utilized in clinical settings and research environments, with a diverse client base that includes hospitals, research institutions, and pharmaceutical companies across North America and Europe. By focusing on enhancing the efficacy of treatments and diagnostics, Advanced Microbubbles aims to improve patient outcomes and streamline medical procedures, catering primarily to markets with a high adoption of advanced healthcare technology. The revenue structure of Advanced Microbubbles Inc.

is derived from B2B transactions involving direct sales of their microbubble products to healthcare providers and research institutions. Partnerships with hospitals and pharmaceutical companies are integral to their business model, enabling the establishment of long-term contracts for specialized microbubble agents. Transactions generally involve bulk purchasing agreements, where clients order products based on specific needs for medical applications, such as contrast-enhanced ultrasound imaging or targeted drug delivery. Advanced Microbubbles' flagship products are positioned within premium pricing tiers, reflecting their unique technological advancements and efficacy in clinical applications.

By focusing on cultivating strong relationships with their client base, the company aims to secure consistent revenue streams through contract renewals and ongoing partnerships within the healthcare sector. Advanced Microbubbles Inc. plans to introduce new microbubble products aimed at improving drug delivery and diagnostic capabilities, with potential launches anticipated in the next two years. The company is targeting expansion into the European market, specifically in countries with growing healthcare infrastructure, by 2023.

The funding raised in May 2020 will be utilized to support the development of these new products and to establish partnerships with healthcare institutions in Europe.